Amiodarone or an Implantable Cardioverter–Defibrillator for Congestive Heart Failure

Abstract

In patients with NYHA class II or III CHF and LVEF of 35 percent or less, amiodarone has no favorable effect on survival, whereas single-lead, shock-only ICD therapy reduces overall mortality by 23 percent.

Keywords

MedicineAmiodaroneEjection fractionHazard ratioHeart failureCardiologyInternal medicinePlaceboImplantable cardioverter-defibrillatorSudden deathConfidence intervalSudden cardiac deathClinical endpointRandomized controlled trialAtrial fibrillation

Affiliated Institutions

Related Publications

Dual-Chamber Pacing or Ventricular Backup Pacing in Patients With an Implantable Defibrillator

Bruce L. Wilkoff , James R. Cook , Andrew E. Epstein +5 more

For patients with standard indications for ICD therapy, no indication for cardiac pacing, and an LVEF of 40% or less, dual-chamber pacing offers no clinical advantage over ventr...

2002 JAMA 2014 citations

Cardiac-Resynchronization Therapy with or without an Implantable Defibrillator in Advanced Chronic Heart Failure

Michael R. Bristow , Leslie A. Saxon , John Boehmer +9 more

In patients with advanced heart failure and a prolonged QRS interval, cardiac-resynchronization therapy decreases the combined risk of death from any cause or first hospitalizat...

2004 New England Journal of Medicine 5754 citations

Canadian Implantable Defibrillator Study (CIDS)

Stuart J. Connolly , Michael Gent , Robin S. Roberts +7 more

Background —Patients surviving ventricular fibrillation (VF) or sustained ventricular tachycardia (VT) are at a high risk of death due to a recurrence of arrhythmia. The implant...

2000 Circulation 1589 citations

A Comparison of Antiarrhythmic-Drug Therapy with Implantable Defibrillators in Patients Resuscitated from Near-Fatal Ventricular Arrhythmias

The Antiarrhythmics versus Implantable Defibrillators Investigators

Among survivors of ventricular fibrillation or sustained ventricular tachycardia causing severe symptoms, the implantable cardioverter-defibrillator is superior to antiarrhythmi...

1997 New England Journal of Medicine 3203 citations

The Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial

Bruce L. Wilkoff

Introduction: The devices used to prove the benefit of ICD therapy had only VVI pacing but most current ICD devices provide dual chamber pacing therapy. The DAVID trial sought t...

2003 Pacing and Clinical Electrophysiology 35 citations

Publication Info

Year: 2005
Type: article
Volume: 352
Issue: 3
Pages: 225-237
Citations: 6444
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Amiodarone or an Implantable Cardioverter–Defibrillator for Congestive Heart Failure

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

6444

OpenAlex

Cite This

APA Style

                            
                                
                                    Gust H. Bardy, 
                                
                                    Kerry L. Lee, 
                                
                                    Daniel B. Mark
                                
                                et al.
                            
                            (2005). 
                            Amiodarone or an Implantable Cardioverter–Defibrillator for Congestive Heart Failure. 
                            New England Journal of Medicine
                            , 352
                            (3)
                            , 225-237.
                            https://doi.org/10.1056/nejmoa043399
                        

Identifiers

DOI: 10.1056/nejmoa043399